Table 1.
Baseline demographic and clinical characteristics of the enrolled participants.
| Variables | VBQ group (n=193) |
VA group (n=193) |
VD group (n=193) |
P-value |
|---|---|---|---|---|
| Sex (Male/Female) | 93/100 | 84/109 | 102/91 | 0.186 |
| Age (years) | 49.55 ± 11.64 | 46.76 ± 12.95 | 48.25 ± 12.67 | 0.095 |
| BMI (kg/m2) | 24.34 ± 3.37 | 23.24 ± 3.04 | 23.31 ± 3.33 | 0.002 |
| Medical history | ||||
| Hypertension | 35 (18.1%) | 24 (12.4%) | 39 (20.2%) | 0.108 |
| Diabetes | 13 (6.7%) | 10 (5.2%) | 16 (8.3%) | 0.476 |
| Hyperlipidemia | 17 (8.8%) | 10 (5.2%) | 15 (7.8%) | 0.368 |
| Coronary Heart Disease | 1 (0.5%) | 2 (1.0%) | 6 (3.1%) | 0.093 |
| Other | 15 (7.8%) | 24 (12.4%) | 26 (13.5%) | 0.168 |
| Smoking history | 59 (30.6%) | 37 (19.2%) | 60 (31.1%) | 0.012 |
| Alcohol consumption history | 85 (44.0%) | 64 (33.2%) | 81 (42.0%) | 0.068 |
| Previous eradication therapy | 16 (8.3%) | 8 (4.1%) | 9 (4.7%) | 0.160 |
| Recent Gastrointestinal Symptoms | 63 (32.6%) | 78 (40.4%) | 100 (51.8%) | 0.001 |
| Antibiotic use in past 2 years | ||||
| Amoxicillin/Penicillin | 57 (29.5%) | 52 (26.9%) | 59 (30.6%) | 0.721 |
| Clarithromycin | 10 (5.2%) | 9 (4.7%) | 11 (5.7%) | 0.900 |
| Metronidazole/Tinidazole | 9 (4.7%) | 7 (3.6%) | 14 (7.3%) | 0.254 |
| Levofloxacin | 29 (15.0%) | 17 (8.8%) | 27 (14.0%) | 0.143 |
| Furazolidone | 2 (1.0%) | 0 | 1 (0.5%) | 0.366 |
| Tetracycline | 1 (0.5%) | 0 | 1 (0.5%) | 0.605 |
| Cephalosporin | 67 (34.7%) | 55 (28.5%) | 53 (27.5%) | 0.244 |
| Other/Unknown | 16 (8.3%) | 20 (10.4%) | 24 (12.4%) | 0.410 |
VBQ, vonoprazan-bismuth-amoxicillin-doxycycline quadruple therapy; VA, vonoprazan-amoxicillin dual therapy; VD, vonoprazan-doxycycline dual therapy; BMI, body mass index; H. pylori, Helicobacter pylori.